Pharmacy based dosing of darbepoetin in haemodialysis patients of the Sint Franciscus Gasthuis

Pharmacy based dosing of darbepoetin in haemodialysis patients of the Sint Franciscus Gasthuis - Pharmacy based dosing of darbepoetin in haemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33197

Enrollment

200

Registered

2009-09-09

Start date

2010-05-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anaemia end stage renal disease

Interventions

In the intervention group, the pharmacist advizes the nephrologist regarding the dosage of darbepoetin and iron based on recent haemoglobin values and iron status, as well as previous dosages of dar

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All haemodialysis patients treated with darbepoetin

Exclusion criteria

Exclusion criteria: Patients with less than three prospective haemoglobin values included in data analysis

Design outcomes

Primary

Measure	Time frame
Which percentage of haemodialysis patients reaches haemoglobin values within the target range (6.8-7.4 mmol/l) with darbepoetin dosage defined by nephrologist alone compared with dosage defined by pharmacist and nephrologist?	—

Secondary

Measure	Time frame
1. Which part of haemodialysis patients before and after intervention reaches haemoglobin values within the target range (6.8-7.4 mmol/l) with darbepoetin dosage defined by nephrologist alone compared with darbepoetin dosage defined by pharmacist and nephrologist? 2. Which percentage of the haemoglobin values per patient lies within the target range before and after intervention, for the group treated by nephrologist alone as well as for the group treated by nephrologist and phamacist together? 3. Which proportion of haemodialysis patients before and after intervention reaches haemoglobin values within the wider target range (6.8-8.1 mmol/l) with darbepoetin dosage defined by nephrologist alone and with darbepoetin dosage defined by nephrologist and pharmacist together? 4. Which percentage of the pharmacist's advices is not acted on by the nephrologist and why? 5. Which percentage of haemodialysis patients before and after intervention has an adequate iron status with treatment defined by nephrologist alone compared with treatment defined by nephrologist and pharmacist together?	—

Measure

Time frame

1. Which part of haemodialysis patients before and after intervention reaches haemoglobin values within the target range (6.8-7.4 mmol/l) with darbepoetin dosage defined by nephrologist alone compared with darbepoetin dosage defined by pharmacist and nephrologist? 2. Which percentage of the haemoglobin values per patient lies within the target range before and after intervention, for the group treated by nephrologist alone as well as for the group treated by nephrologist and phamacist together? 3. Which proportion of haemodialysis patients before and after intervention reaches haemoglobin values within the wider target range (6.8-8.1 mmol/l) with darbepoetin dosage defined by nephrologist alone and with darbepoetin dosage defined by nephrologist and pharmacist together? 4. Which percentage of the pharmacist's advices is not acted on by the nephrologist and why? 5. Which percentage of haemodialysis patients before and after intervention has an adequate iron status with treatment defined by nephrologist alone compared with treatment defined by nephrologist and pharmacist together?

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)